RedHill Biopharma (RDHL) Non-Current Assets (2012 - 2025)
RedHill Biopharma (RDHL) posted quarterly Non-Current Assets of $18.8 million for Q4 2025, up 206.87% year-over-year from $6.1 million in Q4 2024, and up 223.32% quarter-over-quarter from $5.8 million in Q2 2025.
RedHill Biopharma (RDHL) Non-Current Assets (2012 - 2025) Analysis & Trends
RedHill Biopharma (RDHL) has reported Non-Current Assets for 14 consecutive years, with $18.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets rose 206.87% year-over-year to $18.8 million; the TTM figure through Dec 2025 stood at $37.2 million (up 506.64% YoY), while the FY2025 annual figure was $18.8 million, up 206.87% from the prior year.
- Non-Current Assets improved to $18.8 million in Q4 2025 per RDHL's latest filing, from $5.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $105.2 million in Q2 2021 and bottomed at $5.8 million in Q2 2025.
- Historically, Non-Current Assets has averaged $39.9 million across 5 years, with a median of $13.4 million in 2023.
- Annual changes were most pronounced in 2023 — Non-Current Assets plunged 90.53% — and 2025, when it soared 206.87%.
- RedHill Biopharma's Non-Current Assets stood at $92.0 million in 2021, then fell by 20.72% to $73.0 million in 2022, then slumped by 90.53% to $6.9 million in 2023, then declined by 11.22% to $6.1 million in 2024, then jumped by 206.87% to $18.8 million in 2025.
- Business Quant data shows RDHL's Non-Current Assets at $18.8 million in Q4 2025, $5.8 million in Q2 2025, and $6.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | 18.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.82 Mn |
| Jun 30, 2025 | 5.82 Mn |
| Dec 31, 2024 | 6.13 Mn |
| Jun 30, 2024 | 6.32 Mn |
| Dec 31, 2023 | 6.91 Mn |
| Jun 30, 2023 | 7.99 Mn |
| Dec 31, 2022 | 72.97 Mn |
| Jun 30, 2022 | 76.70 Mn |
| Dec 31, 2021 | 92.04 Mn |
| Jun 30, 2021 | 105.18 Mn |
| Dec 31, 2020 | 109.75 Mn |
| Jun 30, 2020 | 105.24 Mn |
| Dec 31, 2019 | 20.89 Mn |
| Jun 30, 2019 | 9.72 Mn |
| Dec 31, 2018 | 5.62 Mn |
| Jun 30, 2018 | 5.63 Mn |
| Mar 31, 2018 | 5.66 Mn |
| Dec 31, 2017 | 5.67 Mn |
| Dec 31, 2016 | 6.40 Mn |
| Mar 31, 2015 | 6.33 Mn |